Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company have announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of comparators (placebo, glimepiride and voglibose).
AstraZeneca selects location for new global R&D centre and corporate headquarters
- Details
- Category: AstraZeneca
AstraZeneca announced that its new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a highly-skilled workforce of approximately 2,000.
MedImmune, AstraZeneca's biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity.
Bristol-Myers Squibb and Simcere enter partnership to co-develop and co-commercialize Orencia® SC (abatacept) in China
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis.
Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent
- Details
- Category: Pfizer
Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk" launches of generic Protonix® in the United States.
New four-strain influenza vaccine from Sanofi Pasteur now licensed by FDA
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine. Fluzone Quadrivalent vaccine is the newest addition to the Fluzone family of influenza vaccines.
More Pharma News ...
- AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
- Boehringer Ingelheim pioneers biopharmaceuticals move to China
- FDA grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin
- Sanofi provides update on Phase 3 studies of two investigational compounds
- Amgen and Astellas announce Japan Alliance
- Novartis launches a new campaign to raise awareness of MS
- AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio